Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834272 · ClinicalTrials.gov registry record · Phase 1
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
A Phase 1 study, sponsored by Lumicell.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03834272 is a Phase 1 study that has completed, run by Lumicell. The registered enrollment target is 18 participants.
The verdict
NCT03834272, a Phase 1 study, has completed, sponsored by Lumicell.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The objective of this feasibility study is to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and mesothelioma. This feasibility study consists of a dose escalation phase to select the optimal dose.
Interventions
- COMBINATION_PRODUCT LUM Imaging System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2025-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834272
The ClinicalTrials.gov registry entry for NCT03834272 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumicell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LUM Imaging System is the first listed.
NCT03834272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03834272 about?
NCT03834272 is a clinical study titled "Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies". The objective of this feasibility study is to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and mesothelioma. This feasibility study consists of a dose escalation phase to sele...
What is the current status of trial NCT03834272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-03-18. Estimated completion is 2025-08-19.
What interventions are being tested in trial NCT03834272?
The interventions under investigation include: LUM Imaging System (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03834272?
This trial is sponsored by Lumicell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.